BioSpace News Archive

Pharma-Bio Serv, Inc. today announced that the Board of Directors approved a Special Dividend of $0.075 per share for Shareholders.

Celsion Corporation today announced financial results for the three and nine months ended September 30, 2021, and provided an update

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company committed to being the leader in responsible pain management, announced that it has entered into an Accelerated Share Repurchase agreement with Jefferies LLC to repurchase $25 million of the Company’s common stock.

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is celebrating their biggest event of the year with consumers all over the United States.

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today reports its financial results and provides an update on its operational progress for the third quarter and nine months ended September 30, 2021.

Akebia Therapeutics, Inc. today announced that John P. Butler , Chief Executive Officer, will present at the Jefferies London Healthcare Conference, which takes place November 16 – 19, 2021.

Thermo Fisher Scientific Inc., the world leader in serving science, today announced innovative proteomics solutions and a series of co-marketing agreements with industry experts, advancing the throughput, comprehensiveness and quality of proteomics workflows for applications such as single-cell studies and translational research.

Nektar Therapeutics (NASDAQ: NKTR) today announced it has appointed Diana M. Brainard , M.D., as an independent director to its Board of Directors.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has acquired Combangio, Inc., a private, clinical-stage company developing regenerative biotherapies for severe ocular surface diseases.

Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease with potential first-in-class nanotherapeutics, today announced the completion of enrollment in the HEALEY ALS Platform Trial,